{
 "id": "epjh5szj3w",
 "slug": "mark-c-petrie",
 "title": "Mark C. Petrie",
 "updated": "2026-10-21",
 "topic_path": [
  {
   "id": "life",
   "label": "Life and health",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life"
  },
  {
   "id": "life.scientists",
   "label": "Life and health scientists",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.scientists"
  },
  {
   "id": "life.scientists.medicine-health",
   "label": "Medical and health researchers",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.scientists.medicine-health"
  },
  {
   "id": "life.scientists.medicine-health.med-cardio",
   "label": "Researchers in cardiovascular, metabolic, and endocrine research",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.scientists.medicine-health.med-cardio"
  },
  {
   "id": "life.scientists.medicine-health.med-cardio.heart-failure-researchers",
   "label": "Heart failure researchers",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.scientists.medicine-health.med-cardio.heart-failure-researchers"
  },
  {
   "id": "life.scientists.medicine-health.med-cardio.heart-failure-researchers.clinical-and-health-services-researchers",
   "label": "Clinical and health services researchers",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.scientists.medicine-health.med-cardio.heart-failure-researchers.clinical-and-health-services-researchers"
  }
 ],
 "geo": [
  {
   "id": "geo.weu.t1946.life.scientists.medicine-health.med-cardio.heart-failure-researchers",
   "label": "Western Europe · 1946 to 2000: Heart failure researchers",
   "api_url": "https://www.edgepedia.org/api/v1/geo/geo.weu.t1946.life.scientists.medicine-health.med-cardio.heart-failure-researchers",
   "path": [
    {
     "id": "geo.weu",
     "label": "Western Europe",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.weu"
    },
    {
     "id": "geo.weu.t1946",
     "label": "Western Europe · 1946 to 2000",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.weu.t1946"
    },
    {
     "id": "geo.weu.t1946.life",
     "label": "Life and health",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.weu.t1946.life"
    },
    {
     "id": "geo.weu.t1946.life.scientists",
     "label": "Life and health scientists",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.weu.t1946.life.scientists"
    },
    {
     "id": "geo.weu.t1946.life.scientists.medicine-health",
     "label": "Medical and health researchers",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.weu.t1946.life.scientists.medicine-health"
    },
    {
     "id": "geo.weu.t1946.life.scientists.medicine-health.med-cardio",
     "label": "Researchers in cardiovascular, metabolic, and endocrine research",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.weu.t1946.life.scientists.medicine-health.med-cardio"
    },
    {
     "id": "geo.weu.t1946.life.scientists.medicine-health.med-cardio.heart-failure-researchers",
     "label": "Heart failure researchers",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.weu.t1946.life.scientists.medicine-health.med-cardio.heart-failure-researchers"
    }
   ]
  }
 ],
 "excerpt": "Mark C. Petrie is a Scottish cardiologist and Professor of Cardiology at the University of Glasgow, known for heart failure research and the STEP-HFpEF semaglutide trial.",
 "snippet": "Mark C. Petrie is a Scottish cardiologist and Professor of Cardiology at the University of Glasgow, known for heart failure research and the STEP-HFpEF semaglutide trial.",
 "node": "life.scientists.medicine-health.med-cardio.heart-failure-researchers.clinical-and-health-services-researchers",
 "markdown": "# Mark C. Petrie\n\n**Mark C. Petrie** is a cardiologist and Professor of Cardiology in the School of Cardiovascular and Metabolic Health at the [University of Glasgow](https://www.edgepedia.org/university-of-glasgow), and a cardiologist at Glasgow Royal Infirmary.<sup>[1](https://www.gla.ac.uk/schools/cardiovascularmetabolic/staff/markpetrie/)</sup> He also practices at the Golden Jubilee National Hospital in Glasgow.<sup>[2](https://www.heartrhythmcongress.org/speakers/view/1230)</sup> His research centers on heart failure, especially heart failure with preserved ejection fraction (HFpEF), and the question of whether restoring blood flow helps a weakened heart, and he has held leadership roles in trials including REVIVED, STEP-HFpEF, DAPA-HF, EMPACT-MI, IRONMAN, PARADISE-MI, and FINEARTS.<sup>[1](https://www.gla.ac.uk/schools/cardiovascularmetabolic/staff/markpetrie/)</sup>\n\n| Key facts | |\n|---|---|\n| Position | Professor of Cardiology, School of Cardiovascular and Metabolic Health, University of Glasgow<sup>[1](https://www.gla.ac.uk/schools/cardiovascularmetabolic/staff/markpetrie/)</sup> |\n| Clinical posts | Cardiologist at Glasgow Royal Infirmary and the Golden Jubilee National Hospital<sup>[2](https://www.heartrhythmcongress.org/speakers/view/1230)</sup> |\n| Training | Undergraduate studies at Edinburgh University; cardiology training in Glasgow<sup>[3](https://www.radcliffecardiology.com/authors/mark-petrie?language_content_entity=en)</sup> |\n| Academic post | Moved to the University of Glasgow in 2016 after years in clinical practice<sup>[3](https://www.radcliffecardiology.com/authors/mark-petrie?language_content_entity=en)</sup> |\n| Signature work | STEP-HFpEF trial of semaglutide in HFpEF with obesity, New England Journal of Medicine, 2023<sup>[4](https://www.nejm.org/doi/full/10.1056/NEJMoa2306963)</sup> |\n| Other landmark trials | REVIVED-BCIS2 (NEJM, 2022) and the GOAL-HF1 study of the oral ghrelin receptor agonist AC01 (The Lancet, 2026)<sup>[5](https://www.nejm.org/doi/full/10.1056/NEJMoa2206606)</sup><sup> • </sup><sup>[6](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00904-9/abstract)</sup> |\n| Service roles | Deputy Editor of the European Journal of Heart Failure; joined the boards of the Heart Failure Association of the ESC and the British Society of Heart Failure<sup>[1](https://www.gla.ac.uk/schools/cardiovascularmetabolic/staff/markpetrie/)</sup> |\n\n## Training and career\n\nPetrie began as an undergraduate at Edinburgh University, then trained in cardiology in Glasgow.<sup>[3](https://www.radcliffecardiology.com/authors/mark-petrie?language_content_entity=en)</sup> He spent many years in clinical practice as a heart failure and interventional cardiologist before transferring to an academic post at the University of Glasgow in 2016.<sup>[3](https://www.radcliffecardiology.com/authors/mark-petrie?language_content_entity=en)</sup> He worked as an interventional and heart failure/transplant cardiologist, and his trial portfolio spans both revascularization and medical therapy.<sup>[1](https://www.gla.ac.uk/schools/cardiovascularmetabolic/staff/markpetrie/)</sup>\n\n## Clinical and academic roles\n\nPetrie continues to see patients at Glasgow Royal Infirmary and the Golden Jubilee National Hospital.<sup>[2](https://www.heartrhythmcongress.org/speakers/view/1230)</sup> He became Deputy Editor of the European Journal of Heart Failure, joined the board of the Heart Failure Association of the [European Society of Cardiology](https://www.edgepedia.org/european-society-of-cardiology), where he chairs its HFpEF/HFmrEF group, and joined the board of the British Society of Heart Failure.<sup>[1](https://www.gla.ac.uk/schools/cardiovascularmetabolic/staff/markpetrie/)</sup> He became co-chair of the Scottish Cardiac Audit Programme and chairs the Clinical Board of the Pumping Marvellous Foundation.<sup>[1](https://www.gla.ac.uk/schools/cardiovascularmetabolic/staff/markpetrie/)</sup> In guideline work he was an author of the ESC NSTEMI guidelines and a reviewer of the ESC heart failure guidelines.<sup>[2](https://www.heartrhythmcongress.org/speakers/view/1230)</sup> He has also chaired or served on more than 40 Clinical Events Committees for major trials, including EMPAREG-OUTCOME, and DELIVER.<sup>[1](https://www.gla.ac.uk/schools/cardiovascularmetabolic/staff/markpetrie/)</sup>\n\n## Representative work\n\n**STEP-HFpEF** enrolled 500+ patients with HFpEF and a body-mass index of 30 or higher, who were randomly assigned to once-weekly semaglutide 2.4 mg or placebo for 52 weeks, in a study funded by [Novo Nordisk](https://www.edgepedia.org/novo-nordisk).<sup>[4](https://www.nejm.org/doi/full/10.1056/NEJMoa2306963)</sup> The mean change in the Kansas City Cardiomyopathy Questionnaire clinical summary score was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points), and the mean percentage change in body weight was −13.3% with semaglutide and −2.6% with placebo (estimated difference, −10.7 percentage points).<sup>[4](https://www.nejm.org/doi/full/10.1056/NEJMoa2306963)</sup> Six-minute walk distance rose about 20 m versus about 1 m, and the hierarchical composite endpoint favored semaglutide with a win ratio of about 1.7.<sup>[4](https://www.nejm.org/doi/full/10.1056/NEJMoa2306963)</sup> Serious adverse events appeared less frequent on the drug (roughly 10–20% versus 20–30%), only about 1 semaglutide participant versus 10+ on placebo had an adjudicated heart failure hospitalization or urgent visit (hazard ratio 0.08), and [C-reactive protein](https://www.edgepedia.org/c-reactive-protein) fell substantially (about 35% versus under 10%).<sup>[4](https://www.nejm.org/doi/full/10.1056/NEJMoa2306963)</sup><sup> • </sup><sup>[7](https://pubmed.ncbi.nlm.nih.gov/37622681/)</sup> A prespecified analysis showed the symptomatic and walking gains grew with the amount of weight lost, 6.4 points and 14.4 m per 10% of body weight, tying the benefit to weight reduction itself.<sup>[8](https://www.nature.com/articles/s41591-023-02526-x)</sup>\n\n## Revascularization and early-phase drug work\n\n**REVIVED-BCIS2** asked a long-standing question: in patients whose heart muscle is underperfused but viable, does opening the arteries help? The trial randomized about 560 patients with a left ventricular ejection fraction of 35% or less and extensive coronary disease amenable to percutaneous coronary intervention (PCI) to PCI plus optimal medical therapy or medical therapy alone, funded by the NIHR Health Technology Assessment Programme.<sup>[5](https://www.nejm.org/doi/full/10.1056/NEJMoa2206606)</sup> Over a median of 41 months, death from any cause or hospitalization for heart failure occurred in 37.2% of the PCI group versus 38.0% on medical therapy alone (hazard ratio 0.99; 95% CI 0.78 to 1.27; P=0.96).<sup>[5](https://www.nejm.org/doi/full/10.1056/NEJMoa2206606)</sup> [Ejection fraction](https://www.edgepedia.org/ejection-fraction) did not improve more with PCI, and there was no sustained quality-of-life difference at a median of 3.4 years.<sup>[5](https://www.nejm.org/doi/full/10.1056/NEJMoa2206606)</sup>\n\nIn 2026 he co-authored **GOAL-HF1**, a phase 1b/2a study of AC01, a novel oral calcium-sensitizing inotrope and ghrelin receptor agonist, in heart failure with reduced ejection fraction (HFrEF), a condition whose central problem is reduced contractility.<sup>[9](https://eprints.gla.ac.uk/390366/)</sup> Between 23 February 2023 and 28 August 2025, about 50 patients (median age 66.0 years) were randomly assigned at about 10 sites in the Netherlands, the UK, Sweden, and Italy: about 25 in phase 1b dose-escalation cohorts of 0.1 to 3.0 mg twice daily for 7 days, and about 20 in phase 2a receiving 1 mg, 3 mg, or placebo twice daily for 28 days.<sup>[6](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00904-9/abstract)</sup><sup> • </sup><sup>[10](https://anacardio.com/anacardios-phase-1b-2a-goal-hf1-study-in-patients-with-heart-failure-and-reduced-ejection-fraction-hfref-published-in-the-lancet/)</sup> There were no AC01-related serious adverse events and no deaths; mild or moderate treatment-emergent adverse events occurred in about 26 of 41 patients on AC01 and about 10 of 17 on placebo.<sup>[6](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00904-9/abstract)</sup> The authors concluded that AC01 over 28 days appeared safe and well tolerated, supporting investigation in larger studies.<sup>[6](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00904-9/abstract)</sup>\n\n## Recent developments\n\nThe STEP-HFpEF program expanded. A companion trial in patients who also had type 2 diabetes reported 7 adjudicated heart failure events on semaglutide versus 18 on placebo (hazard ratio 0.40).<sup>[11](https://pubmed.ncbi.nlm.nih.gov/38587233/)</sup> A 2024 pooled analysis of the two trials, 1,145 participants in total, found hospitalization or an urgent visit for heart failure in 1% of the semaglutide group versus 5% of the placebo group (hazard ratio 0.27; 95% CI 0.12 to 0.56), and a lower risk of adjudicated cardiovascular death or heart failure event (hazard ratio 0.31; 95% CI 0.15 to 0.62).<sup>[12](https://doi.org/10.1016/s0140-6736(24)00469-0)</sup>\n\nOn the AC01 side, according to its [ClinicalTrials.gov](https://www.edgepedia.org/clinicaltrials-gov) record, the sponsor AnaCardio AB registered a phase 2 follow-up, GOAL-HF2 (NCT07584967), a randomised, double-blind, placebo-controlled multicentre study of two dose levels of oral AC01 over 12 weeks in chronic advanced HFrEF, with a start date of 15 September 2026 and estimated enrollment of 400 participants.<sup>[13](https://clinicaltrials.gov/study/NCT07584967)</sup> \n\n## References\n\n1. Professor Mark Petrie, University of Glasgow staff profile. https://www.gla.ac.uk/schools/cardiovascularmetabolic/staff/markpetrie/\n2. Mark Petrie, HRC 2026 faculty profile. https://www.heartrhythmcongress.org/speakers/view/1230\n3. Mark Petrie, Radcliffe Cardiology author profile. https://www.radcliffecardiology.com/authors/mark-petrie?language_content_entity=en\n4. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF), NEJM 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2306963\n5. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction (REVIVED-BCIS2), NEJM 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206606\n6. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00904-9/abstract\n7. STEP-HFpEF abstract record, PubMed. https://pubmed.ncbi.nlm.nih.gov/37622681/\n8. Semaglutide in HFpEF across obesity class, Nature Medicine 2023. https://www.nature.com/articles/s41591-023-02526-x\n9. GOAL-HF1 article record, University of Glasgow Enlighten repository. https://eprints.gla.ac.uk/390366/\n10. AnaCardio's Phase 1b/2a GOAL-HF1 study published in The Lancet. https://anacardio.com/anacardios-phase-1b-2a-goal-hf1-study-in-patients-with-heart-failure-and-reduced-ejection-fraction-hfref-published-in-the-lancet/\n11. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes (STEP-HFpEF DM), PubMed. https://pubmed.ncbi.nlm.nih.gov/38587233/\n12. https://doi.org/10.1016/s0140-6736(24)00469-0\n13. GOAL-HF2 (NCT07584967), ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07584967\n\n---\n*Topic: Encyclopedia › Life and health › Life and health scientists › Medical and health researchers › Researchers in cardiovascular, metabolic, and endocrine research › Heart failure researchers › Clinical and health services researchers*\n\n*Initially written Sep 21, 2026 · Reviewed: Sep 25, 2026; Sep 30, 2026 · Edited: Sep 25, 2026; Sep 30, 2026; Oct 11, 2026; Oct 15, 2026; Oct 21, 2026 · Last review: Sep 30, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n",
 "same_as": [],
 "url": "https://www.edgepedia.org/mark-c-petrie",
 "markdown_url": "https://www.edgepedia.org/mark-c-petrie.md",
 "license": {
  "name": "Edgepedia Community License 1.0",
  "url": "https://www.edgepedia.org/edgepedia/license",
  "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.",
  "spdx": "LicenseRef-Edgepedia-Community-1.0"
 },
 "credit": "\"Mark C. Petrie\", Edgepedia (EdgeChat), https://www.edgepedia.org/mark-c-petrie. Edgepedia Community License 1.0.",
 "credit_md": "\"[Mark C. Petrie](https://www.edgepedia.org/mark-c-petrie)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/mark-c-petrie](https://www.edgepedia.org/mark-c-petrie). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).",
 "credit_html": "\"<a href=\"https://www.edgepedia.org/mark-c-petrie\">Mark C. Petrie</a>\", Edgepedia (EdgeChat), <a href=\"https://www.edgepedia.org/mark-c-petrie\">https://www.edgepedia.org/mark-c-petrie</a>. <a href=\"https://www.edgepedia.org/edgepedia/license\">Edgepedia Community License 1.0</a>.",
 "speakable": "Mark C. Petrie is a Scottish cardiologist and Professor of Cardiology at the University of Glasgow, known for heart failure research and the STEP-HFpEF semaglutide trial."
}